Market Should Be Giving Much More Credit to Latest Deal
The deal with Projects in Knowledge is the ideal type of partnership for CLRX. This deal will get Therapy Finder distribution, understanding, awareness, and integration into thousands of oncologists...EXACTLY the type of deal you want.
The deal with LIFE Technologies will begin to generate revenue in 2014 on the molecular diagnostic side. That deal will enable physicians and healthcare providers to match increasingly DNA-specific molecular tests with knowledge of DNA-specific drug and clinical trial work...helping bring personalized medicine to the clinic to create more effective outcomes, and lower healthcare costs.
All physicians must get CME credits every year, and the focus of Projects in Knowledge, is just that...to provide education to physicians across many specialties. This deal means that The Therapy Finder, with its increasing knowledge base of 4 cancers (and more on the way), will become known as a first-line tool among oncologists.
With these two deal, CollabRx has established its brand...both on the education side and at the clinic.
I have been a critic of Thomas Mika, only because of the massive loss of shareholder value and the number of poor investments he's had to write-off, during his time as CEO of Tegal...all while making substantial compensation. However, the deal to acquire CLRX...and the partnerships that have been established this year (without a COO and without a real seasoned partnership deal maker), are starting to become impressive. I am a firm believer in the future of personalized medicine. DNA testing is becoming widespread and increasingly specific. Drug development, with the opening of the human genome, is becoming increasingly specific. CLRX is establishing itself in the middle of this major, long-term trend, by providing the tools to help physicians put two-and-two together.
If Mika, and his team, can continue to generate these types of deals, shareholder confidence will return. The stock is super cheap.